Pathological indicators such as tumor size, axillary lymph node metastasis, and histological grade, as well as molecular biological indicators such as estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER-2), and ki-67 are currently used to guide the prognosis of breast cancer patients (4). This evidence concerns the gene ERBB2 and breast carcinoma.